First Patient Dosed in Global Randomized Ph 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma July 17, 2024
Development of Early-Stage Bispecific T-Cell Engager AMG 794 for Solid Tumors discontinued July 17, 2024
Ph 1/2 dose-escalation study of SP-2577 in combination with azacitidine in adults with MDS and CMML Placed on Partial Hold July 17, 2024
Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Announced July 9, 2024
Focus on vebreltinib study enrollment for NSCLC patients with Met Amplification mutations announced July 9, 2024
Three Community Cancer Centers Activated as First Sites for the Pivotal Ph 2 ALPHA3 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Consolidation Treatment for Patients with LBCL July 9, 2024
Ph 3 TrilynX study of xevinapant + CRT in patients with unresected LA SCCHN to be discontinued July 1, 2024
Type C meeting with FDA supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC) concluded July 1, 2024
Third Independent Safety Review of Ph 3 ASPIRE Clinical Trial Announced; DSMB Recommended Continuation with No Trial Modification July 1, 2024
First-Patient-In Announced for Ph 1 Trial of IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer July 1, 2024
Database Lock announced for Ph 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer July 1, 2024
Planned Combination Strategy for EO-3021 in Patients with Gastric or GEJ Cancer Announced July 1, 2024
FDA places partial clinical hold on Ph 1 ZN-c3-001 in solid tumors, Ph 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and Ph 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC) of azenosertib June 25, 2024
SEACRAFT-2 Pivotal Ph 3 Trial of Naporafenib + Trametinib Initiated in Patients with NRAS-Mutant Melanoma June 25, 2024
GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated June 25, 2024
Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated June 25, 2024
Recruitment completed for CLINGLIO, the Ph 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed GBM June 18, 2024
